» Articles » PMID: 39277578

Mcam Stabilizes a Luminal Progenitor-like Breast Cancer Cell State Via Ck2 Control and Src/Akt/Stat3 Attenuation

Overview
Date 2024 Sep 14
PMID 39277578
Authors
Affiliations
Soon will be listed here.
Abstract

Cell state control is crucial for normal tissue development and cancer cell mimicry of stem/progenitor states, contributing to tumor heterogeneity, therapy resistance, and progression. Here, we demonstrate that the cell surface glycoprotein Mcam maintains the tumorigenic luminal progenitor (LP)-like epithelial cell state, leading to Basal-like mammary cancers. In the Py230 mouse mammary carcinoma model, Mcam knockdown (KD) destabilized the LP state by deregulating the Ck2/Stat3 axis, causing a switch to alveolar and basal states, loss of an estrogen-sensing subpopulation, and resistance to tamoxifen-an effect reversed by Ck2 and Stat3 inhibitors. In vivo, Mcam KD blocked generation of Basal-like tumors and Sox10+Krt14+ cells. In human tumors, MCAM loss was largely exclusive of the Basal-like subtype, linked instead to proliferative Luminal subtypes, including often endocrine-resistant Luminal B cancers. This study has implications for developing therapies targeting MCAM, CK2, and STAT3 and their likely effective contexts.

References
1.
Orstad G, Fort G, Parnell T, Jones A, Stubben C, Lohman B . FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma. Dev Cell. 2022; 57(15):1866-1882.e10. PMC: 9378547. DOI: 10.1016/j.devcel.2022.06.017. View

2.
Yeo S, Zhu X, Okamoto T, Hao M, Wang C, Lu P . Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer. Elife. 2020; 9. PMC: 7447441. DOI: 10.7554/eLife.58810. View

3.
Shih L, Hsu M, Palazzo J, Herlyn M . The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol. 1997; 151(3):745-51. PMC: 1857834. View

4.
Lundgren K, Holm K, Nordenskjold B, Borg A, Landberg G . Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. Breast Cancer Res. 2008; 10(5):R81. PMC: 2614516. DOI: 10.1186/bcr2150. View

5.
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E . Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014; 32(25):2794-803. DOI: 10.1200/JCO.2013.54.1870. View